Working… Menu

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02296918
Recruitment Status : Active, not recruiting
First Posted : November 21, 2014
Last Update Posted : September 18, 2019
Information provided by (Responsible Party):
Acerta Pharma BV

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2022